Internal Medicine, Hematology & Oncology · Laredo, TX
NPI
1285673012
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
2344 Laguna del Mar Ct, Suite 104
Laredo, TX, 78041
Phone (956) 724-8543
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
62,599 services
Medicare patients, 2024
312
Average age 74
Drug cost, 2024
$7.5M
1,382 prescriptions
Company payments, 2025
$8,447
From 45 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Eduardo Miranda was code J0897 (injection, denosumab, 1 mg), 3,960 times for 12 patients. In total Eduardo Miranda billed 62,599 services in 84 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,960 | 12 | $20.70 | $82K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,024 | 19 | $0.09 | $180 |
| J1750 Injection, iron dextran, 50 mg | Office | 919 | 39 | $13.10 | $12K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 650 | 11 | $0.69 | $446 |
| 99213 Office E&M - Established | Office | 388 | 194 | $67.44 | $26K |
| 99214 Office E&M - Established | Office | 366 | 152 | $98.72 | $36K |
| 96367 Intravenous Infusion, Hydration | Office | 269 | 58 | $22.44 | $6,038 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 200 | 50 | $0.65 | $130 |
| 96413 Chemotherapy Administration | Office | 190 | 28 | $101.06 | $19K |
| 96365 Intravenous Infusion, Hydration | Office | 158 | 58 | $47.05 | $7,434 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 154 | 13 | $4.51 | $695 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 97 | 11 | $135.39 | $13K |
| 96372 Injection Administration | Office | 95 | 21 | $10.74 | $1,020 |
| 96366 Intravenous Infusion, Hydration | Office | 79 | 37 | $16.06 | $1,269 |
| 96415 Chemotherapy Administration | Office | 75 | 11 | $22.11 | $1,658 |
By year: 2022 $2.7M for 150,234 services; 2023 $1.9M for 114,488 services; 2024 $1.2M for 62,599 services.
Medicare prescription drug claims, 2024
In 2024, the drug Eduardo Miranda prescribed most often to Medicare patients was Anastrozole, with 110 prescriptions and refills. In total Eduardo Miranda wrote 1,382 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 110 | 213 | 36 | $977 |
| Hydroxyurea Generic | 55 | 87 | 15 | $994 |
| Inlyta Axitinib | 48 | 48 | Under 11 | $886K |
| Xtandi Enzalutamide | 47 | 47 | Under 11 | $590K |
| Kisqali Ribociclib Succinate | 46 | 46 | Under 11 | $775K |
| Letrozole Generic | 44 | 87 | 16 | $761 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 39 | 39 | 21 | $491 |
| Ondansetron Odt Ondansetron | 36 | 37 | 32 | $805 |
| Xgeva Denosumab | 35 | 35 | Under 11 | $113K |
| Bicalutamide Generic | 30 | 38 | Under 11 | $445 |
| Alendronate Sodium Generic | 29 | 55 | 12 | $158 |
| Megestrol Acetate Generic | 26 | 31 | 19 | $2,091 |
| Tasigna Nilotinib Hcl | 25 | 25 | Under 11 | $245K |
| Levothyroxine Sodium Generic | 22 | 36 | Under 11 | $125 |
| Erleada Apalutamide | 22 | 22 | Under 11 | $341K |
Brand drugs: 545 claims; generic drugs: 837 claims; opioid claims: 97.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Eduardo Miranda $8,447 ($8,447 in general payments such as food, travel and fees) from 45 companies. The largest payer was OnMark, Inc. with $2,992.
| Company | Payments | Amount |
|---|---|---|
| OnMark, Inc. | 10 | $2,992 |
| Janssen Biotech, Inc. JNJ | 18 | $523 |
| AstraZeneca Pharmaceuticals LP AZN | 17 | $367 |
| Pfizer Inc. PFE | 24 | $344 |
| GlaxoSmithKline, LLC. GSK | 13 | $316 |
| Sobi, Inc SOBI.ST | 6 | $260 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $253 |
| Genentech USA, Inc. ROG.SW | 10 | $226 |
| PharmaEssentia USA Corporation 6446.TW | 5 | $212 |
| Incyte Corporation INCY | 6 | $203 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.